These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 27998284)

  • 1. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
    Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
    Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Generation and comparison of two genetically engineered mouse models of ErbB2/Neu positive-PTEN deficient breast cancer].
    Wang QF; Ding H; Liu BR; Zhang K
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 43(4):427-33. PubMed ID: 25187457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. USP22 overexpression fails to augment tumor formation in MMTV-ERBB2 mice but loss of function impacts MMTV promoter activity.
    Kuang X; Salinger A; Benavides F; Muller WJ; Dent SYR; Koutelou E
    PLoS One; 2024; 19(1):e0290837. PubMed ID: 38236941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
    Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
    Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.
    Brantley-Sieders DM; Zhuang G; Hicks D; Fang WB; Hwang Y; Cates JM; Coffman K; Jackson D; Bruckheimer E; Muraoka-Cook RS; Chen J
    J Clin Invest; 2008 Jan; 118(1):64-78. PubMed ID: 18079969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of glucose transporter 1 (GLUT1) expression levels alters mouse mammary tumor cell growth in vitro and in vivo.
    Young CD; Lewis AS; Rudolph MC; Ruehle MD; Jackman MR; Yun UJ; Ilkun O; Pereira R; Abel ED; Anderson SM
    PLoS One; 2011; 6(8):e23205. PubMed ID: 21826239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity.
    Sriram R; Lo V; Pryce B; Antonova L; Mears AJ; Daneshmand M; McKay B; Conway SJ; Muller WJ; Sabourin LA
    Breast Cancer Res; 2015 Jan; 17(1):7. PubMed ID: 25592291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis.
    Dong Y; Van Tine BA; Oyama T; Wang PI; Cheng EH; Hsieh JJ
    Cell Res; 2014 Nov; 24(11):1354-66. PubMed ID: 25267403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
    Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
    Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The LIM domain binding protein 1, Ldb1, has distinct roles in Neu-induced mammary tumorigenesis.
    Ahmed S; Pryce BR; Al-Zahrani KN; Sabourin LA
    Biochim Biophys Acta Mol Cell Res; 2018 Nov; 1865(11 Pt A):1590-1597. PubMed ID: 30327200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A moderate elevation of circulating levels of IGF-I does not alter ErbB2 induced mammary tumorigenesis.
    Dearth RK; Kuiatse I; Wang YF; Liao L; Hilsenbeck SG; Brown PH; Xu J; Lee AV
    BMC Cancer; 2011 Aug; 11():377. PubMed ID: 21867536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated expression of DecR1 impairs ErbB2/Neu-induced mammary tumor development.
    Ursini-Siegel J; Rajput AB; Lu H; Sanguin-Gendreau V; Zuo D; Papavasiliou V; Lavoie C; Turpin J; Cianflone K; Huntsman DG; Muller WJ
    Mol Cell Biol; 2007 Sep; 27(18):6361-71. PubMed ID: 17636013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERBB2 overexpression suppresses stress-induced autophagy and renders ERBB2-induced mammary tumorigenesis independent of monoallelic Becn1 loss.
    Lozy F; Cai-McRae X; Teplova I; Price S; Reddy A; Bhanot G; Ganesan S; Vazquez A; Karantza V
    Autophagy; 2014 Apr; 10(4):662-76. PubMed ID: 24492513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
    Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
    Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of cancer progression reveals intrinsic regulation of transforming growth factor-beta signaling in ErbB2/Neu-induced tumors from transgenic mice.
    Landis MD; Seachrist DD; Montañez-Wiscovich ME; Danielpour D; Keri RA
    Oncogene; 2005 Aug; 24(33):5173-90. PubMed ID: 15897883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways.
    Andrade-Vieira R; Xu Z; Colp P; Marignani PA
    PLoS One; 2013; 8(2):e56567. PubMed ID: 23451056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
    Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
    Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
    Nie J; Dang S; Zhu R; Lu T; Zhang W
    Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.
    Klover PJ; Muller WJ; Robinson GW; Pfeiffer RM; Yamaji D; Hennighausen L
    Neoplasia; 2010 Nov; 12(11):899-905. PubMed ID: 21076615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
    Peng M; Ball-Kell SM; Tyner AL
    Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.